CD19 and Burkitt lymphoma: These results demonstrate that CD19/20/22CAR T-cells can mediate an effective CARIS with CD19(−) BL-ALL targets and can exhibit robust antitumor immune reactivity and retain considerable polyfunctionality in the face of CD19 loss.